Jaroslaw Leszczyszyn

Jaroslaw Leszczyszyn

Auto-generated profile, based on publicly available information

Jaroslaw Leszczyszyn

EMC HC Clinic, Dublin, Republic of Ireland

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
ARAnna Radomska
Anna Radomska
JLJaroslaw Leszczyszyn
Jaroslaw Leszczyszyn
MRMarek Witold Radomski
Marek Witold Radomski
The very dynamic growth of nanotechnology, nanomaterials (sized 1-100 nm) and their medical applications over the past 10 years has promised to add a new impetus to the diagnostics and therapeutics of a wide range of human pathologies, including cancer, cardiovascular diseases and diseases of the central nervous system. This growth in nanomedicine also fuels advances in bioengineering, regenerative medicine and the development of medical devices. However, as with all new pharmaceuticals and medical devices, new opportunities are inherently accompanied by new challenges due to the ability of nanomaterials to interact with the body on the cellular, subcellular and molecular levels. This article reviews some of the most compelling problems related to the nanopharmacology and nanotoxicology of nanomaterials. The overview focuses on opportunities emerging from the development of multifunctional nanomaterials and nanotheranostics for the diagnostics and therapy of both major and rare diseases. Challenges related to the hemocompatibility of nanomaterials are also discussed.

30 December 2014 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
KNKamil H. Nelke
Kamil H. Nelke
WPWojciech Pawlak
Wojciech Pawlak
HGHanna Gerber
Hanna Gerber
JLJarosław Leszczyszyn
Jarosław Leszczyszyn
Advances in Clinical and Experimental Medicine jest oficjalnym pismem Uniwersytetu Medycznego im. Piast?w Sl?skich we Wroc?awiu. Publikowane s? w nim prace naukowe polskie, jak r?wnie? zagraniczne.

30 April 2014 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
JLJarosław Leszczyszyn
Jarosław Leszczyszyn
IŁIgor Łebski
Igor Łebski
LŁLidia Łysenko
Lidia Łysenko
LHLidia Hirnle
Lidia Hirnle
HGHanna Gerber
Hanna Gerber
HPV infections are currently the most frequent cause of genital infections in the USA. Risk factors are early onset of sexual activity, multiple sexual partners, a history STDs, an early age of first pregnancy and tobacco use. In the past, HPV viruses were thought to be STDs, but it is now known that penetration is not necessary. Skin-to-skin or mucosa-to-mucosa contact is enough to transmit the virus, which presents high tropism for those tissues. The Papillomaviridae family includes over 120 viruses, some of which have high malignant transformation rates. The most common malignancy connected to HPV is uterine cervix cancer and anal canal cancer. The range of morphology of perianal lesions means that a thorough clinical examination is required, including an anoscopy. Therapeutic modalities often seek to eliminate macroscopic changes rather than focus on the cause of the infection, which leads to a high recurrence rate. Externally located changes can be eliminated with patient-applied treatments. Those located in the anal canal and distal end of the rectal ampulla require treatment by a qualified medical provider. Due to the high recurrence rate after standard treatment, special attention has been given to vaccinations. The polyvalent vaccine includes HPV viruses with both low and high malignant transformation risk. This has led to a decrease in the rate of malignancies.

3 February 2014 in Postępy Higieny I Medycyny Doświadczalnej
Verified
Journal Article
Open access
KNKamil H Nelke
Kamil H Nelke
WPWojciech Pawlak
Wojciech Pawlak
JLJarosław Leszczyszyn
Jarosław Leszczyszyn
HGHanna Gerber
Hanna Gerber
Photodynamic therapy (PDT) is a special type of treatment involving the use of a photosensitizer or a photosensitizing agent along with a special type of light, which, combined together, induces production of a form of oxygen that is used to kill surrounding cells in different areas of the human body. Specification of the head and neck region requires different approaches due to the surrounding of vital structures. PDT can also be used to treat cells invaded with infections such as fungi, bacteria and viruses. The light beam placed in tumor sites activates locally applied drugs and kills the cancer cells. Many studies are taking place in order to invent better photosensitizers, working on a larger scale and to treat deeply placed and larger tumors. It seems that PDT could be used as an alternative surgical treatment in some tumor types; however, all clinicians should be aware that the surgical approach is still the treatment of choice. PDT is a very accurate and effective therapy, especially in early stages of head and neck squamous cell carcinomas (HNSCC), and can greatly affect surgical outcomes in cancerous patients. We present a detailed review about photosensitizers, their use, and therapeutic advantages and disadvantages.

30 May 2013
Verified
Book Chapter
Closed access
PDF file
LHL. Hirnle
L. Hirnle
LLL. Lysenko
L. Lysenko
HGH. Gerber
H. Gerber
PLP. Lesnik
P. Lesnik
ABA. Baranowska
A. Baranowska
LSL. Strozecki
L. Strozecki

29 February 2016 in Rheumatology
Verified
Journal Article
Open access
JLJarosław Jerzy Leszczyszyn
Jarosław Jerzy Leszczyszyn
MRMarek Radomski
Marek Radomski
ALAnna Maria Leszczyszyn
Anna Maria Leszczyszyn
Faecal microbiota transplantation (FMT) has induced a lot scientific interest and hopes for the last couple of years. FMT has been approved as a treatment of recurrent Clostridium difficile colitis. Highly sophisticated molecular DNA identification methods have been used to assess the healthy human microbiome as well as its disturbances in several diseases. The metabolic and immunologic functions of the microbiome have become more clear and understandable. A lot of pathological changes, such as production of short-chain fatty acids or components of the inflammatory cascade, caused by changes in microbiome diversity, variability and richness have been observed among patients suffering from inflammatory bowel diseases, irritable bowel syndrome, type 2 diabetes or rheumatoid arthritis. The published clinical results are encouraging, but still there is huge demand for FMT controlled clinical trials.